drugset / Trial / NCT07219212

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07219212

Phase 1 Recruiting 45 enrolled Johnson & Johnson Enterprise Innovation Inc.
NaSingle-groupOpen-labelTreatment

Summary

This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).

Timeline

Start
2026-01-26
Primary completion
2028-07-14
Completion
2028-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-90301900 Other / unclassified Other
Background Carboplatin Small molecule Intravenous
Background Cisplatin Other / unclassified Intravenous
Background Paclitaxel Small molecule Intravenous